Peripheral T-Cell Lymphomas (PTCL) - Pipeline Review, H1 2016

Description: Peripheral T-Cell Lymphomas (PTCL) - Pipeline Review, H1 2016

Summary

‘Peripheral T-Cell Lymphomas (PTCL) - Pipeline Review, H1 2016’, provides an overview of the Peripheral T-Cell Lymphomas (PTCL) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Peripheral T-Cell Lymphomas (PTCL), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Peripheral T-Cell Lymphomas (PTCL) and features dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Peripheral T-Cell Lymphomas (PTCL)
- The report reviews pipeline therapeutics for Peripheral T-Cell Lymphomas (PTCL) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Peripheral T-Cell Lymphomas (PTCL) therapeutics and enlists all their major and minor projects
- The report assesses Peripheral T-Cell Lymphomas (PTCL) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Peripheral T-Cell Lymphomas (PTCL)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Peripheral T-Cell Lymphomas (PTCL)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Peripheral T-Cell Lymphomas (PTCL) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Contents:

List of Tables
List of Figures
Introduction
Report Coverage
Peripheral T-Cell Lymphomas (PTCL) Overview
Therapeutics Development
Pipeline Products for Peripheral T-Cell Lymphomas (PTCL) - Overview
Peripheral T-Cell Lymphomas (PTCL) - Therapeutics under Development by Companies
Peripheral T-Cell Lymphomas (PTCL) - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Peripheral T-Cell Lymphomas (PTCL) - Products under Development by Companies
Peripheral T-Cell Lymphomas (PTCL) - Companies Involved in Therapeutics Development
AB Science SA
Affimed Therapeutics AG
Bayer AG
Celgene Corporation
CerRx, Inc.
Chipscreen Biosciences Ltd
Eisai Co., Ltd.
Incyte Corporation
Johnson & Johnson
Karyopharm Therapeutics, Inc.
Mundipharma International Ltd
Ono Pharmaceutical Co., Ltd.
Onxeo SA
Pfizer Inc.
Rhizen Pharmaceuticals S.A.
Seattle Genetics, Inc.
Solasia Pharma K.K.
Spectrum Pharmaceuticals, Inc.
TG Therapeutics, Inc.
Peripheral T-Cell Lymphomas (PTCL) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AFM-13 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
belinostat - Drug Profile
Product Description
Mechanism of Action
R&D Progress
brentuximab vedotin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
copanlisib hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CS-055 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
darinaparsin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
denileukin diftitox - Drug Profile
Product Description
Mechanism of Action
R&D Progress
fenretinide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
forodesine hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
lenalidomide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
masitinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
mitoxantrone hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
nivolumab - Drug Profile
Product Description
Mechanism of Action
Mechanism of Action
R&D Progress
TGR-1202 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
tipifarnib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Peripheral T-Cell Lymphomas (PTCL) - Recent Pipeline Updates
Peripheral T-Cell Lymphomas (PTCL) - Dormant Projects
Peripheral T-Cell Lymphomas (PTCL) - Discontinued Products
Peripheral T-Cell Lymphomas (PTCL) - Product Development Milestones
Featured News & Press Releases
Dec 22, 2015: Huya Bioscience International Announces Orphan Drug Designation For HBI-8000 In Japan
Dec 07, 2015: Seattle Genetics Highlights ADCETRIS Data Presentations in Frontline Non-Hodgkin Lymphoma at ASH 2015
Dec 06, 2015: Spectrum Pharmaceuticals and Onxeo Announce Complete Response in 67% of Patients with Peripheral T-Cell Lymphoma in Combination of Belinostat and Standard CHOP
Nov 09, 2015: Onxeo Reports Initial Results of Phase 1 Trial Evaluating Belinostat in Combination with CHOP in Peripheral T-cell Lymphoma
Sep 30, 2015: Kura Oncology Initiates Phase 2 Study of Tipifarnib in Peripheral T-cell Lymphoma
Jun 23, 2015: Beleodaq (belinostat) pivotal BELIEF study results published in the Journal of Clinical Oncology
May 27, 2015: AB Science: Phase 2 with masitinib in peripheral T-cell lymphoma accelerated into phase 3
Jan 09, 2015: Chipscreen Biosciences Announces CFDA Approval of Chidamide (Epidaza) for PTCLs in China
Dec 09, 2014: Combination of ISTODAX (romidepsin) and Standard CHOP Demonstrates a Complete Response in 51% of Patients with Peripheral T-Cell Lymphoma
Dec 05, 2014: Spectrum Pharmaceuticals Highlights Abstracts on Beleodaq (belinostat) at the 56th Annual Meeting of the ASH in San Francisco
Appendix
Methodology
Coverage
Secondary Research
Number of Products under Development for Peripheral T-Cell Lymphomas (PTCL), H1 2016
Number of Products under Development by Companies, H1 2016
Comparative Analysis by Late Stage Development, H1 2016
Comparative Analysis by Clinical Stage Development, H1 2016
Comparative Analysis by Early Stage Development, H1 2016
Products under Development by Companies, H1 2016
Products under Development by Companies, H1 2016 (Contd..1)
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by AB Science SA, H1 2016
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Affimed Therapeutics AG, H1 2016
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Bayer AG, H1 2016
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Celgene Corporation, H1 2016
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by CerRx, Inc., H1 2016
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Chipscreen Biosciences Ltd, H1 2016
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Eisai Co., Ltd., H1 2016
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Incyte Corporation, H1 2016
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Johnson & Johnson, H1 2016
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Karyopharm Therapeutics, Inc., H1 2016
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Mundipharma International Ltd, H1 2016
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Onxeo SA, H1 2016
 Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Pfizer Inc., H1 2016
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Rhizen Pharmaceuticals S.A., H1 2016
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Seattle Genetics, Inc., H1 2016
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Solasia Pharma K.K., H1 2016
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2016
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by TG Therapeutics, Inc., H1 2016
Assessment by Monotherapy Products, H1 2016
Number of Products by Stage and Target, H1 2016
Number of Products by Stage and Mechanism of Action, H1 2016
Number of Products by Stage and Route of Administration, H1 2016
Number of Products by Stage and Molecule Type, H1 2016
Peripheral T-Cell Lymphomas (PTCL) Therapeutics - Recent Pipeline Updates, H1 2016
Peripheral T-Cell Lymphomas (PTCL) - Dormant Projects, H1 2016
Peripheral T-Cell Lymphomas (PTCL) - Discontinued Products, H1 2016
List of Figures
Number of Products under Development for Peripheral T-Cell Lymphomas (PTCL), H1 2016
Number of Products under Development by Companies, H1 2016
Comparative Analysis by Clinical Stage Development, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Assessment by Monotherapy Products, H1 2016
Number of Products by Top 10 Targets, H1 2016
Number of Products by Stage and Top 10 Targets, H1 2016
Number of Products by Top 10 Mechanism of Actions, H1 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
Number of Products by Routes of Administration, H1 2016
Number of Products by Stage and Routes of Administration, H1 2016
Number of Products by Molecule Types, H1 2016
Number of Products by Stage and Molecule Types, H1 2016

Ordering:
Order Online - http://www.researchandmarkets.com/reports/3691109/
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Peripheral T-Cell Lymphomas (PTCL) - Pipeline Review, H1 2016
Web Address: http://www.researchandmarkets.com/reports/3691109/
Office Code: SCPLJFFJ

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Product Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td></td>
<td>USD 2000</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td></td>
<td>USD 4000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td></td>
<td>USD 6000</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [ ] Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof
First Name: __________________________ Last Name: __________________________
Email Address: * __________________________
Job Title: __________________________
Organisation: __________________________
Address: __________________________
City: __________________________
Postal / Zip Code: __________________________
Country: __________________________
Phone Number: __________________________
Fax Number: __________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
  Account number 833 130 83
  Sort code 98-53-30
  Swift code ULSBIE2D
  IBAN number IE78ULSB98533083313083
  Bank Address Ulster Bank,
               27-35 Main Street,
               Blackrock,
               Co. Dublin,
               Ireland.

If you have a Marketing Code please enter it below:

   Marketing Code: ________________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp